セマグルチドとティルゼパチドは,心不全の患者で,エジェクション分子が保存されている
Nils Krüger1,2,3,4, Sebastian Schneeweiss1,2, Kenshiro Fuse1,2
1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
JAMA
|August 31, 2025
まとめ
セマグルチドとティルゼパチドは,心臓代謝性HFpEF患者の心不全の入院と死亡率を著しく減少させた. ティルゼパチドは,セマグルチドに比べ,この患者集団において,追加的な効果を示さなかった.
科学分野:
- 心臓病科
- 内分泌学
- 薬理学について
背景:
- 保存されたエジェクション分数 (HFpEF) による心不全は,しばしば肥満や2型糖尿病などの心代謝疾患を有する個人に影響を与える,入院の重要な原因です.
- HFpEFの症状に対するセマグルチドとティルゼパチドの利点が初期研究で示唆されたが,限られた臨床的イベントによりさらなる調査が必要となった.
研究 の 目的:
- 心臓代謝性HFpEFと診断された患者におけるセマグルチドとティルゼパチドの有効性と安全性を評価する.
- HFpEFの治療におけるセマグルチドと直接のティルゼパチドの有効性を比較する.
主な方法:
- 重要な試験設計 (STEP- HFpEF DM, SUMMIT) を模倣したコホート研究のために,米国の5つの国家医療請求データベース (2018-2024) を利用した.
- 典型的な臨床実務を反映した適格性の基準を拡張し,最大52週間の追跡調査を行った.
- シタグリプチンをプラセボの代理として使用したHF入院または全原因死亡の複合エンドポイントの危険性比を分析する傾向スコアの重み付け.
主要な成果:
- セマグルチドを投与した患者はシタグリプチンと比較してリスクが42%低下 (HR,0. 58; 95% CI,0. 51- 0. 65) し,ティルゼパチドを投与した患者はリスクが58%低下 (HR,0. 42; 95% CI,0. 31- 0. 57) しました.
- ヒト対ヒト比較では,ティルゼパチドとセマグルチドの有意な差異は認められなかった (HR,0. 86;95%CI,0. 70~1. 06).
- ネガティブ・コントロール,二次エンドポイント,サブグループ分析において一貫した結果であり,重大な安全性に関する懸念はありません.
結論:
- セマグルチドとティルゼパチドは,心臓代謝性HFpEFの患者で,HF入院または全因死亡のリスクを大幅に減少させました (40%以上).
- テルゼパチドはセマグルチドと比較して有意な追加効果を示さなかった.
- これらの発見は,セマグルチドがティルゼパチドと同様の選択肢である心臓代謝性HFpEFの管理における両方の薬剤の使用を支持する.
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434